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Abstract
Background: Care for people with amyotrophic lateral sclerosis (ALS) has altered at King’s College Hospital over the last 20
years. The clinic has been a multidisciplinary, specialist, tertiary referral centre since 1995 with a large team with integrated
palliative and respiratory care since 2006. We hypothesised that these changes would improve survival. Methods: In this
retrospective observational study, patients diagnosed with El Escorial definite, probable and possible ALS between 1995–
1998 and 2008–2011 were followed up. The primary outcome measure was a chi-square test for the proportion of each
cohort surviving. Kaplan-Meier survival analysis and Cox multivariate regression were secondary analyses. Results: There
was low reporting of some interventions. Five hundred and forty-seven people were included. Survival between the cohorts
was significantly different (p¼ 0.022) with a higher proportion surviving during 2008–2011. Survival time was 21.6 (95%
CI 19.2–24.0) months in the 2008–2011 cohort compared to 19.2 years (15.6–21.6) in the 1995–1998 cohort (log rank
p¼ 0.018). Four hundred and ninety-three cases were included in the Cox regression. Diagnostic cohort was a significant
predictor variable (HR 0.79 (0.64–0.97) p¼ 0.023). Conclusions: These results support the hypothesis that integrated
specialist clinics with multidisciplinary input improve survival in ALS.
Keywords: Motor neuron disease; amyotrophic lateral sclerosis; multidisciplinary team; multidisciplinary care; survival; care
quality
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disease in which there is progressive loss
of spinal and cortical motor neurons leading to
death from respiratory failure often within a median
of two years (1,2). Because of the devastating nature
of the disease and the impact on patients and
families, specialist clinics with expertise in ALS have
developed, usually with an associated multidiscip-
linary team (MDT), the aim being to improve
quality and quantity of life through better medical
and social care. As well as multidisciplinary care,
three other interventions are widely used in ALS.
Riluzole is used to prolong survival, but the effect is
modest (3,4). There is evidence that non-invasive
ventilation (NIV) as a treatment for neuromuscular
respiratory failure also improves survival as well as
quality of life (5), and gastrostomy is used for
dysphagia impacting nutritional intake (6).
Riluzole, non-invasive ventilation and gastros-
tomy, have only been in use for the last 20 years, and
in widespread use more recently still, largely through
the medium of multidisciplinary teams. Although
riluzole can be prescribed by a neurologist, in the
UK, NIV and gastrostomy for ALS are usually
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accessed through an MDTallied to a specialist clinic
or community team, since they are used at advanced
stages of ALS when needs are complex and
multifaceted.
Clinical data on those attending a specialised
tertiary care centre in South East London have been
collected since 1995 as part of the South East ALS
(SEALS) register. The King’s MND service was
initiated in 1989 and formally established with
multidisciplinary input as the King’s MND Care
and Research Centre in 1995. However, full integra-
tion of specialist nursing, diet planning, physiother-
apy, speech and language therapy, and especially with
respiratory, psychological, and palliative care services
was not achieved until around 2006. Because of the
significant experience base of the team tempered by
geographical confinement, a key strategy has been
exchange of knowledge with local care teams, similar
to other specialist MDTs across the country and in
modern healthcare systems worldwide.
Two studies based in Ireland have previously
shown that multidisciplinary care improves quality
and quantity of life (7,8). In England, a study
comparing survival of people treated at a general
neurology clinic with to those at a specialised
multidisciplinary care clinic also showed the specia-
lised clinic improved survival, although in Italy a
population based study found there was no differ-
ence between people seen in clinics with MDTs and
those not (9,10). It has been proposed that
improved survival is a result of the accurate timing
of interventions by specialist teams (7). The import-
ance of timing of interventions has also been shown
by prognostic modelling (11).
We therefore sought to assess whether survival and
care provision has changed over time by comparing
disease duration in people diagnosed and managed
within the early, small MDT, and those seen 10 years
later and managed within the expanded team with
more sophisticated treatment protocols.
Materials and methods
Data sources
Data were obtained from the SEALS Register,
which has been described previously. This register
is now part of the MND Register for England, Wales
and Northern Ireland which was approved by the
South East London Research Ethics Committee on
01/06/2015 study number 15/LO/0810.
Figure 1 is a consort diagram that summarises
the numbers in each cohort and how many records
were available for analysis.
Study design
We chose two time-periods to study, one beginning in
1995, soon after clinic inception, and the other in
2008, selected to allow comparison between an
evolving MDT and a more integrated and complete
MDT. Power analysis showed that 199 cases in each
group would allow detection of a 10% difference in
survival at p¼ 0.05. We therefore selected four-year
windows following each time-period, so that cohort 1
represented all people diagnosed between 1 January
1995 and 31 December 1998, and cohort 2, all people
diagnosed between 1 January 2008 and 31 December
2011. Cohort 2 was followed for survival to 16 May
2016. To preventbias from very long survivors, cohort
1 was followed for survival to the equivalent date, 16
May 2003. Survival time was calculated from date of
diagnosis, as this is the earliest multidisciplinary care
starts, to death or end date. Where people were lost to
follow-up, the date of the most recent appointment
was used as the end date. Riluzole and NIV data were
collected where available. Data on gastrostomy were
not available for the first cohort, so were not
compared between the cohorts. For cohort 1 the
only NIV data available were from people who were
started on NIV at the tertiary centre. Cohort 2
included everyone who was set up with NIV at the
tertiary centre and a few with documented follow-up
where NIV was set up locally. In both cases the
numbers of people on NIV are low so it is likely that
cases are missing to follow-up.
Statistical methods
Chi square testing of the proportion of people
surviving at the end of each time-point was per-
formed. Univariate survival analysis was by Kaplan-
Meier product limit distribution using the log rank
test. Multivariate analysis was by Cox regression.
The assumption of proportional hazards was
checked by assessing whether diagnostic cohort
was a time-dependent variable, and by assessing a
log minus log survival against log survival time-
graph. For multivariate analysis, we extracted sex,
age of onset, site of onset (bulbar, spinal or other),
onset to diagnosis interval (ODI), date of death or
last follow-up, clinical phenotype (ALS, flail arm
variant ALS, flail limb variant ALS), El Escorial
category, riluzole use. Riluzole use was categorised
using ‘intention to treat’ methodology. If someone
had taken it once and then stopped, this would still
be categorised as use. Where any variables were
missing from a case record, that record was excluded
from analysis involving that variable. Statistical
analyses were carried out using IBM SPSS v22.0
(12). Figure 2 was created using R version 3.3.1
with packages ‘ggplot2’, ‘survival’,
‘RcmdrPlugin.KMggplot2’ (13–17). All variables
except sex were included in the Cox analysis as
these have previously been described as having an
effect on survival. Including sex as a covariate did
not change the model. For comparison between El
Escorial categories, as there were no ‘clinically-
probable laboratory supported’ cases in the 1995
cohort, ‘probable’ and ‘clinically-probable
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laboratory supported’ were grouped together as
‘probable’ and analysed together throughout.
Analysing the data with ‘clinically-probable, labora-
tory supported’ grouped with ‘possible’ did not
change the model. We performed a sensitivity
analysis to account for the possibility of missing
NIV data by labelling the top 50% of survivors in
each cohort as having received NIV.
Results
Demographic characteristics of the two cohorts are
shown in Table 1. Median time from onset to
diagnosis was a month higher in cohort 2, and
riluzole and NIV use were significantly higher in this
cohort. Otherwise the two groups were similar.
There was a greater percentage of people alive in
cohort 2 than cohort 1 at the endpoint of the study,
15% in cohort 2 compared with 8% in cohort 1 and
this difference was significant (p¼ 0.02).
The median survival time was 19.2 (95% CI
15.6–21.6) months for cohort 1 compared with 21.6
(95% CI 19.2–24.0) months for cohort 2 (log-rank
test p¼ 0.018).
Figure 2 shows the Kaplan-Meier survival curves
generated. Because three important prognostic fac-
tors, riluzole, NIV use, and diagnostic delay, were
not balanced between the two cohorts, we per-
formed a multivariate analysis using a Cox propor-
tional hazards survival model; the results are
summarised in Table 2.
Figure 1. Consort diagram showing numbers of cases included in each outcome analysis.
Figure 2. Kaplan-Meier graph showing proportion of people alive
at different time points. The dotted line is the 2008-2011 cohort,
the solid line shows the 1995–1998 cohort. We have shown the
95% confidence intervals on the graph, indicated by the shaded
areas and dotted lines. Overlap of the confidence intervals does
not demonstrate lack of statistical significance (24).
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The Cox regression model demonstrated a
survival benefit for those people in cohort 2 (HR
0.79 (95% CI 0.64–0.97) p¼ 0.023) that could not
be explained only by increased use of riluzole, NIV
or increased diagnostic delay. Sensitivity analyses
were performed to test whether the grouping of
explanatory variables used (described in the
Methods and Figure 2 legend) changed the outcome
of the model with respect to the cohort. We found
that cohort remained an independent predictor of
survival in the model and being diagnosed in the
later cohort was beneficial for survival. Recoding the
top 50% of survivors in each cohort as NIV users
made no difference to cohort being a significant
variable in the model, despite NIV becoming a
significant covariate in the Cox regression.
The test of proportional hazards was met based
on graphical criteria. Additionally, running the Cox
regression with diagnostic cohort as a time- depend-
ent covariate showed that there was no significant
interaction with time (p¼ 0.62).
The model explained approximately 3.8% of the
variation in survival times for the cohorts, with age
of onset accounting for more than 2% and diagnos-
tic cohort just 0.1%, although this is still more than
the contribution of riluzole (Table 3).
Discussion
There was a significant improvement in survival
time of people who were diagnosed with ALS in the
four years from January 2008 compared with those
diagnosed in the four years from January 1995.
Taking into account other confounding covariates,
people diagnosed with ALS in the more recent
cohort survived 2.5 months longer than those in the
earlier cohort. In an exploratory analysis restricted
to people with a diagnosis of ALS (excluding flail
arm and flail leg variants), the median survival
difference was 4.5 months higher in cohort 2 than
cohort 1 (16.1 (95% CI 13.0–17.2) compared
with 20.6 (18.4–22.8)) and this was also significant
(log-rank p-value ¼ 0.007) and was a significant
predictor in the multivariate analysis using the same
covariates as in our main model (HR 0.74 (95% CI
Table 1. Summary statistics showing the case mix of each cohort.
Variable
1995–1998
(n¼217)
2008–2011
(n¼330) Comparison (test)
Mean age at onset (years) 58.7 58.1 p-value ¼0.6 (t test)
Median diagnostic delay (months) 11.0 12.0 p-value ¼0.014 (Mann-Whitney U)
Cases missing date of onset n (%) 0 5 (1.5)
Sex (M:F %) 62:38 59:41 p-value ¼0.49 (Chi squared)
Median survival from diagnosis (months) 19.2 21.6 p-value ¼0.018 (Log rank)
Site of onset n (%)
Bulbar 68 (31.3) 84 (25.5) p-value ¼0.25 (Fisher’s exact test)
Spinal 149 (68.7) 243 (73.6)
Not recorded 0 3 (0.9)
El Escorial n (%)
Definite 72 (33.2) 85 (25.7) p-value ¼0.17 (Fisher’\s exact test)
Probable (including clinically probable laboratory supported) 91 (41.9) 163 (49.3)
Possible 48 (22.8) 68 (20.8)
Not recorded 6 (2.8) 14 (4.2)
ALS subtype n (%)
ALS 194 (89.4) 289 (87.3) p-value ¼0.56 (Chi squared test)
Flail limb variant 23 (10.6) 41 (12.7)
Riluzole use n (%) 75 (34.6) 201 (60.9) p-value ¼<0.001 (Chi squared test)
Riluzole use not recorded n (%) 34 (10.3)
NIV recorded n (%) 13 (6) 44 (13.3) p-value ¼0.006 (chi squared test)
Table 2. Results of the Cox proportional hazards survival
analysis. The El Escorial Category clinically-probable, laboratory
supported only appeared in cohort 2 (2008–2011) and was
grouped together with probable for the analysis. Site of onset was
classified into bulbar and spinal. Spinal onset included people
with respiratory and limb onset. One person had cognitive onset
reported only, and as the diagnosis was of ALS rather than a
bulbar subtype, they were classed as spinal onset ALS.
Variable
Standard
error p-value
Hazard ratio
(95% CI)
Age at onset 0.004 <0.001 1.04 (1.03–1.05)
Diagnostic delay 0.004 <0.001 0.98 (0.97–0.99)
Riluzole
Not prescribed 1
Prescribed 0.11 0.09 0.83 (0.67–1.03)
NIV use
Not recorded as used 1
Used 0.16 0.97 0.99 (0.73–1.36)
El Escorial Category
Definite 1
Probable 0.13 <0.001 0.64 (0.50–0.82)
Possible 0.15 <0.001 0.59 (0.44–0.79)
Site of onset
Bulbar 1
Spinal 0.13 0.77 1.04 (0.81–1.33)
Diagnosis
ALS 1
Flail limb 0.18 <0.001 0.49 (0.34–0.70)
Cohort
1995–1998 1
2008–2011 0.10 0.02 0.79 (0.64–0.97)
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0.60–0.92)). This study supports previous studies
that have shown that multidisciplinary care
improves survival in people with ALS (7–9).
This study uses a different design from most
previous studies because we have tested the same
centre at different time-points before and after a
fully integrated MDT was in place, rather than
different centres at the same times, one with and one
without an MDT. Our study examines the effect of
a highly specialised large MDT with integrated
services, coordination with local teams, and imple-
mentation of cutting edge practice into standard
of care. However, the use of historical controls
for comparison of survival estimates may be flawed
if unmeasurable systemic differences between
cohorts cause the shift in disease trajectory, rather
than the factor of interest.
Some cohort differences can be controlled for by
inclusion of baseline characteristics in multivariate
analysis. The only baseline variable that was signifi-
cantly different between the groups was diagnostic
delay, which was longer in cohort 2. It is not clear
why this is. Higher population levels may lead to
more pressure on the healthcare system increasing
waiting times or, as education and outreach in the
area cause increase in local clinician speciality, a
formal confirmation at the tertiary centre may not
be as urgent for initiation of some care. In support of
this possibility, cohort 2 was larger than cohort 1 by
113 people. A relationship between high patient
volumes and better outcomes is well documented,
although it has not been studied extensively in ALS
(19). It is not clear whether care is improved
through the extra experience gained, whether
better services receive more referrals through repu-
tation, or if both of these are true, representing a
positive feedback loop (20). Alternatively, it could
be another artefact of increased population levels.
Finally, specialist centres may increase knowledge
and recognition of the disease. This is predicted to
shift the population under study from more preva-
lent to incident, and if this is the case, we may be
underestimating the survival difference (21).
A strength of this study is that the centre acts as
its own control. All the specialists seeing patients
from cohort 1 were also seeing patients from
cohort 2. Thus, differences in survival cannot be
attributed to centre effects or systemic differences in
practice. However, this also leads to a weakness of
the study, since care itself has changed over the
time-period studied, with use of non-invasive ven-
tilation (NIV) and nutritional intervention with
gastrostomy now part of routine care. NIV use has
been steadily increasing over time. In 2010 the UK
National Institute for Health and Clinical
Excellence published the NIV guideline for MND
which stated that NIV was cost effective.
We included available NIV data in the Cox
proportional hazards model as people on NIV had
improved survival as shown by Kaplan-Meier ana-
lysis and the provision of NIV recorded between
cohorts was significantly different. There was almost
no change to the Cox proportional hazards model
with or without NIV status, but this may be because
of missing data. NIV is set up in the tertiary centre
which is where the NIV data for this study come
from. Due to the low levels of NIV set up in this
study we estimate we are missing data from com-
munity services. It has been shown that for people
with respiratory impairment, NIV can improve
median survival by 48 days, and maintain quality
of life scores, with a differential benefit for those
without significant bulbar involvement (5). The
difference in survival between our cohorts was 105
days, over twice the benefit reported for NIV.
Furthermore, our sensitivity analysis in which we
artificially boosted the effect of NIV, making it a
significant predictor of survival, did not alter the
survival advantage of the second cohort. We there-
fore cautiously conclude that the MDT provides
benefits that are additional to provision of interven-
tions alone, although trial evidence on the benefits
of early NIV is needed to confirm this. Regardless,
the improvement in survival can be taken to show
that, since it is likely that gastrostomy and NIV
improve outcomes, the specialist team uses these
treatment strategies and others effectively.
Although we were able to fit a highly significant
survival model, the variation in survival time the
model variables could explain was low. This is not
unusual in modelling. For example, despite highly
significant genetic associations in a genome-wide
study of seven million genetic variants in 40,000
people, only about 10% of heritability is explained,
with almost none explained by highly significant
associations (22). Many different genetic, environ-
mental and other factors influence ALS survival,
explaining why the proportion of variance explained
by our model is low (23).
Table 3. Variation in data explained by model. Pseudo r-squared
values were calculated using McFadden’s method (18). The total
variation was calculated using McFadden’s method on the overall
model and by adding the calculation from each explanatory
variable. As they vary slightly both values are presented here.
Covariate Variation explained (%)
Cohort 0.09
Diagnostic delay 0.38
Age of onset 2.22
El Escorial category 0.66
Phenotype 0.42
Site of onset 0
Riluzole 0.07
NIV 0
Total variation explained 3.84 (calculated by adding each
covariate value)
3.79 (calculated using
McFadden’s method on overall
model)
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We have shown that survival of people attending
a specialist ALS clinic has improved over a 13-year
period, and that this effect is probably not fully
accounted for by improvements in treatments avail-
able during that time. This supports the notion that
specialist integrated multidisciplinary care provides
benefit in ALS that can be measured in survival
improvement. It provides evidence that integration
of palliative care services, respiratory care and
wheelchair therapists, along with an MDT meeting,
can improve outcomes in ALS. Further work is
needed to determine whether the benefit of an
MDT also results in improved quality of life.
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